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The majority were male, Caucasian, and insured. Average age
was 59 years old. Based on variable clustering, the XSQ pro-
duced three scales—Xerostomia Interference (9-items), Pain (5-
items), and Nausea and Vomiting Symptoms (3-items). Overall,
internal consistency was acceptable (Cronbach’s alpha coefﬁ-
cients ranged from 0.81–0.96). Construct validity was demon-
strated based on correlations between related items/scales.
Known groups validity was upheld, as HNC patients reported
statistically signiﬁcantly lower scale scores (worse functioning)
than NSCLC patients on all three domains (p < 0.05). As
expected, no statistically signiﬁcant differences were reported
between the groups on the FACT-G scales. CONCLUSIONS:
The XSQ was found to be reliable and valid in this population
and should be a useful tool for clinicians to monitor their
patients. Responsiveness will be evaluated in the future. The
ECHO Registry is currently ongoing.
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OBJECTIVE: Demographic, clinical, social and economic
factors inﬂuence the Health Related Quality of Life (HRQOL)
and must be assessed in the management and treatment of
diverse prostate cancer (PC) patients. The study objective is to
analyze the variations in QoL of newly diagnosed PC patients
over the course of three months between public and private facil-
ities. METHODS: A total of 316 newly diagnosed PC patients
recruited from the urology clinics of a private urban academic
hospital and a veterans hospital completed SF-36 and UCLA-PCI
prior to treatment, and at 3-month follow-up. RESULTS:
General and Prostate-Speciﬁc QoL and demographics were com-
pared across public and private facilities using t-test and chi-sq.
Demographic characteristics varied signiﬁcantly between the two
groups. Privately-treated patients were predominantly Caucasian
(83.68%), whereas publicly-treated patients were predominantly
African American (66.23%, p < 0.0001). Privately-treated
patients had signiﬁcantly higher income and education levels,
and were signiﬁcantly more likely employed and married
(61.35% vs. 20.00%; 54.59% vs. 14.29%). Baseline mean
scores of general QoL demonstrated that publicly-treated
patients were substantially less healthy by physical, psychologi-
cal and social measures (mean physical function score of 47.53
compared to 70.46 for privately-treated patients (p < 0.0001)).
This was true for the PC-speciﬁc HRQoL also, though the dif-
ferences were smaller. After three months, the mean scores for
both groups declined from baseline levels though the groups’ rel-
ative divergence narrowed. Publicly-treated patients remained
substantially less healthy as indicated by general HRQoL scores.
However, for PC-speciﬁc QoL, their means scores on sexual and
urinary function, and sexual and urinary bother were signiﬁ-
cantly higher than privately-treated patients. CONCLUSIONS:
Baseline and 3-month HRQoL of newly diagnosed PC-patients
vary across different treatment settings. Further analysis into the
baseline determinants of QoL and their effect on subsequent
changes in QoL are crucial for effective management of prostate-
cancer. Acknowledgement: Supported by the DOD Prostate
Cancer Research Program DAMD17-02-1-0126.
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OBJECTIVES: Although there is no documented survival differ-
ence between 3-dimensional conformal radiation therapy
(3DCRT) and prostate-brachytherapy (PB), some studies suggest
a quality of life (QOL) advantage with PB. This study assessed
patient preferences for risk of impotence and incontinence after
PB and 3DCRT. METHODS: Preferences for PB were compared
to age, Gleason-grade and pretreatment-PSA matched controls
treated with 3DCRT, using a modiﬁed Time Trade-Off interview.
Men with PB (permanent I-125 implants) were 0.78 to 4.22
(median 2.24) years post treatment (PT) with 145Gy and men
with 3DCRT were 0.75 to 6.07 (median 2.33) years PT with 74
Gy (37 fractions) to the prostate. RESULTS: Preferences were
elicited from 51 men, (17 PB cases vs. 34 3DCRT matched con-
trols). Mean age for the cases and controls were 62.2 years and
63.6 years, respectively. Mean pretreatment-PSA and Gleason
scores were 7.1ng/ml and 5.9 for cases and 6.6ng/ml and 6.0 for
controls, respectively. There were no signiﬁcant differences
among cases and controls regarding race, education or income.
Differences in utilities were assessed using the Wilcoxon Test
(one-sided). Utilities for a 40% risk of impotence were 0.96
(SD.08) for cases and 0.91 (SD.16) for controls, which were not
signiﬁcant (p = 0.09). However, utilities for an 80% risk of impo-
tence were 0.93 (SD.12) for cases and 0.85 (SD.18) for controls
(p = 0.03). Utilities for a 30% risk of incontinence were 0.96
(SD.12) for cases and 0.85 (SD.22) for controls (p = 0.008). Util-
ities for a 10% risk of incontinence were 0.98 (SD.06) for cases
and 0.91 (SD.21) for controls (p = 0.05). CONCLUSIONS:
Patients treated with PB have signiﬁcantly higher utilities for
most levels of risk associated with impotence and incontinence
as compared to those treated with 3DCRT. This is possibly
related to either actual or perceived better sexual and urinary
QOL for PB as compared to 3DCRT.
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OBJECTIVES: To test whether individuals’ responses to stan-
dard gamble (SG) and visual analogue scale (VAS) questions do
not depend on the time horizon of the health scenario presented.
METHODS: Face-to-face interviews were conducted in a con-
venience sample aged 24 to 59 years at a Southern University in
the US (n = 14). Preferences were estimated using SG and VAS.
Individuals rated their preferences for three health states of
varying severity of post chemotherapy nausea and vomiting
(PCNV) assuming different time horizons. Repeated measures
analysis of variance (ANOVA) were conducted (SX6X2) for each
health state to determine the affect of TIME (levels: 3 days, 3
months, 1 year, 5 years, 20 years and rest of life) and METHOD
(levels: SG and VAS) on preference. RESULTS: Analysis showed
that the time horizon used did affect an individual’s preference
rating for SG and VAS. For all three models tested (OP, ST, NV),
main effects TIME (F(5,65) = 10.71, F(5,65) = 13.85, F(5,65) =
17.40) and METHOD (F(1,13) = 34.56, F(1,13) = 58.01, F(1,13)
